ZyVersa Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on the signature page)
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Stephen C. Glover and Peter Wolfe, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her, and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Stephen C. Glover | Chief Executive Officer, President and Chairman | March 25, 2024 |
| Stephen C. Glover | (Principal Executive Officer) | |
| /s/ Peter Wolfe | Chief Financial Officer and Secretary | March 25, 2024 |
| Peter Wolfe | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Robert G. Finizio | Director | March 25, 2024 |
| Robert G. Finizio | ||
| /s/ Min Chul Park, Ph.D. | Director | March 25, 2024 |
| Min Chul Park, Ph.D. | ||
| /s/ James Sapirstein | Director | March 25, 2024 |
| James Sapirstein | ||
| /s/ Gregory Frietag | Director | March 25, 2024 |
| Gregory Frietag | ||
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 688) | F-2 |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | F-3 |
| Balance Sheets as of December 31, 2023 and 2022 | F-4 |
| Statement of Operations for the Year Ended December 31, 2023 (Successor) and the Period December 13, 2022 through December 31, 2022 (Successor), January 1, 2022 through December 12, 2022 (Predecessor) | F-5 |
| Statement of Changes in Stockholders’ Equity for the Successor Period from December 13, 2022 through December 31, 2023 | F-6 |
| Statement of Changes in Stockholder’s Deficiency for the Predecessor Period from January 1, 2022 through December 12, 2022 | F-7 |
| Statements of Cash Flows for the Year Ended December 31, 2023 (Successor) and the Period December 13, 2022 through December 31, 2022 (Successor), January 1, 2022 through December 12, 2022 (Predecessor) | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.